Pulmocide Ltd
Pulmocide is a biopharmaceutical company developing novel inhaled medicines for serious respiratory diseases, with a focus on pulmonary aspergillosis. Their lead product, opelconazole, is in advanced clinical trials for invasive pulmonary aspergillosis, aiming to provide targeted treatment with minimal systemic exposure and reduced side effects.
Industries
Nr. of Employees
small (1-50)
Pulmocide Ltd
44 Southampton Buildings, London, WC2A 1AP, United Kingdom
Patents
Compounds which are used in the preparation of the compound of formula (I)
US-11008307-B2
View DetailsCompounds which are used in the preparation of the compound of formula (II)
US-10800762-B2
View Details
Compounds which are used in the preparation of the compound of formula (I)
US-11008307-B2
View DetailsCompounds which are used in the preparation of the compound of formula (II)
US-10800762-B2
View DetailsProducts
Investigational inhaled triazole antifungal (clinical-stage)
An investigational small-molecule triazole agent formulated for inhalation to maximize lung exposure and minimize systemic uptake; under global clinical development for treatment and prophylaxis of pulmonary aspergillosis and other Aspergillus-associated lung conditions.
Investigational inhaled triazole antifungal (clinical-stage)
An investigational small-molecule triazole agent formulated for inhalation to maximize lung exposure and minimize systemic uptake; under global clinical development for treatment and prophylaxis of pulmonary aspergillosis and other Aspergillus-associated lung conditions.
Services
Collaborative development and licensing partnerships for advancing inhaled respiratory therapeutics through late‑stage clinical programs and regulatory submissions.
Collaborative development and licensing partnerships for advancing inhaled respiratory therapeutics through late‑stage clinical programs and regulatory submissions.
Expertise Areas
- Inhaled drug development for respiratory infections
- Clinical trial management for pulmonary indications (Phases 1–3)
- Pulmonary pharmacokinetics and inhalation PK/PD
- Antifungal preclinical and clinical pharmacology
Key Technologies
- Nebulized inhalation delivery
- Dry powder inhaler formulation (pipeline)
- Aerosol particle-size engineering (~2–3 µm)
- Pulmonary-targeted pharmacokinetic profiling
News & Updates
Pulmocide's CEO will present a corporate update at the J.P. Morgan Healthcare Conference on January 15, 2025.
Inhaled opelconazole was generally well tolerated in a Phase 2 study as prophylaxis against pulmonary aspergillosis in lung transplant patients.
Another presentation by Pulmocide at the J.P. Morgan Conference on January 3, 2024.
Clinical data shows inhaled opelconazole has a low risk for drug-drug interactions, supporting its safety profile.
Pulmocide announced new appointments to its management team on June 8, 2023.
Pulmocide raised $52 million in a Series C extension round to fund late-stage development of opelconazole.
Pulmocide's CEO will present a corporate update at the J.P. Morgan Healthcare Conference on January 15, 2025.
Inhaled opelconazole was generally well tolerated in a Phase 2 study as prophylaxis against pulmonary aspergillosis in lung transplant patients.
Another presentation by Pulmocide at the J.P. Morgan Conference on January 3, 2024.
Clinical data shows inhaled opelconazole has a low risk for drug-drug interactions, supporting its safety profile.
Pulmocide announced new appointments to its management team on June 8, 2023.
Pulmocide raised $52 million in a Series C extension round to fund late-stage development of opelconazole.